| | |
| Clinical data | |
|---|---|
| Trade names | Carafen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.922 |
| Chemical and physical data | |
| Formula | C18H27NO2 |
| Molar mass | 289.419 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Caramiphen is an anticholinergic drug used in the treatment of Parkinson's disease. [1] In combination with phenylpropanolamine it is used as a cough suppressant and nasal decongestant to treat symptoms associated with respiratory illnesses such as cold, allergies, hay fever, and sinusitis. [2] It was added to the British National Formulary in 1963, with a dosage of 10 to 20 mg. Side effects include nausea, dizziness, and drowsiness. [3]
It binds to the sigma-1 receptor with an IC50 value of 25 nM. [4]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
| | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |